Is ISRG's Procedure Growth Enough to Offset Margin Pressures in 2025?

Intuitive Surgical (ISRG) reported strong Q1 2025 results with revenues up 19% to $2.25 billion and da Vinci procedures increasing 17% year-over-year, prompting a raised full-year procedure growth guidance of 15-17%. Despite this robust top-line momentum, gross margins declined to 66.4% from 67.6% due to increased depreciation, a higher mix of lower-margin platforms, and new global tariffs, which are projected to erode margins by 170 basis points for the full year, revising the forecast to 65-66.5%. This puts the focus on whether ISRG's significant procedural volume growth can effectively offset these persistent margin pressures and macroeconomic headwinds, particularly as competitors like Stryker and Medtronic demonstrated improving margins in the same period.

Analysis

Intuitive Surgical (ISRG) demonstrated strong top-line momentum in Q1 2025, with revenues climbing 19% to $2.25 billion, driven by a 17% year-over-year increase in da Vinci procedures. This operational strength, fueled by robust global adoption, prompted management to raise full-year procedure growth guidance to 15-17%. However, this growth is being challenged by significant margin compression. Gross margin declined to 66.4% from 67.6% a year prior, impacted by increased depreciation, a higher mix of lower-margin platforms like the new da Vinci 5, and global tariffs. Consequently, the company revised its full-year gross margin forecast down to 65-66.5%, anticipating a 170 basis point erosion from tariffs alone. This contrasts sharply with competitors Stryker and Medtronic, which reported margin improvements of 190 and 19 basis points, respectively, through efficiencies and pricing power. While ISRG's stock has outperformed its industry year-to-date, its premium forward price-to-earnings ratio of 62.09 now faces pressure from these financial headwinds and potential slowdowns in capital placement due to constrained hospital budgets in key markets.

Key Decisions for Investors

• Investors should critically assess whether Intuitive Surgical's robust procedure growth, guided at 15-17%, can sufficiently offset the forecasted 170 basis point margin erosion from tariffs and other cost pressures.
• Given the stock's premium valuation at a 62.09 forward P/E, any deceleration in procedure volume or further margin decay presents a significant risk to the share price.
• Monitor capital equipment placement rates in key international markets like Germany and Japan, as a slowdown could be a leading indicator of future revenue and margin headwinds.
• Benchmark ISRG's margin performance against peers like Stryker, which successfully expanded margins despite similar tariff pressures, to distinguish company-specific execution issues from broader industry trends.